OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor

Author:

Hariguchi Norimitsu1,Chen Xiuhao1,Hayashi Yohei1,Kawano Yoshikazu2,Fujiwara Mamoru1,Matsuba Miki1,Shimizu Hiroshi2,Ohba Yoshio1,Nakamura Izuru3,Kitamoto Ryuki3,Shinohara Toshio2,Uematsu Yukitaka2,Ishikawa Shunpei2,Itotani Motohiro2,Haraguchi Yoshikazu2,Takemura Isao2,Matsumoto Makoto3

Affiliation:

1. Infectious Diseases Unit, Department of Medical Innovations, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan

2. Medicinal Chemistry Research Laboratories, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan

3. Pharmaceutical Business Division, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan

Abstract

There is an urgent need for new, potent antituberculosis (anti-TB) drugs with novel mechanisms of action that can be included in new regimens to shorten the treatment period for TB. After screening a library of carbostyrils, we optimized 3,4-dihydrocarbostyril derivatives and identified OPC-167832 as having potent antituberculosis activity. The MICs of the compound for Mycobacterium tuberculosis ranged from 0.00024 to 0.002 μg/ml. It had bactericidal activity against both growing and intracellular bacilli, and the frequency of spontaneous resistance for M. tuberculosis H37Rv was less than 1.

Funder

Otsuka Pharmaceutical

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference45 articles.

1. World Health Organization. 2018. Global tuberculosis report 2018. Document WHO/CDS/TB/2018.20. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global_report/en/.

2. Tuberculosis

3. Management of drug-resistant tuberculosis

4. World Health Organization. 2016. Target Regimen Profiles for TB Treatment. World Health Organization, Geneva, Switzerland. https://www.who.int/tb/publications/TRP_profiles/en/.

5. The structural use of carbostyril in physiologically active substances

Cited by 72 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3